(Q35115436)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24612223%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

title

Prediction of the likelihood of drug interactions with kinase inhibitors based on in vitro and computational studies (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24612223%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

author name string

Zhi-Xin Wang

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24612223%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Jiazhi Sun

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24612223%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Qing-Yu Zhou

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24612223%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Zhi-Xu He

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24612223%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Tianxin Yang

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24612223%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Helen Chew

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24612223%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Wei Duan

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24612223%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Zhi-Wei Zhou

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24612223%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Shu-Feng Zhou

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24612223%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

publication date

21 March 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24612223%20AND%20SRC:MED&resulttype=core&format=json

Fundamental and Clinical Pharmacology

10 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24612223%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

volume

28

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24612223%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24612223%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

page(s)

551-582

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24612223%20AND%20SRC:MED&resulttype=core&format=json

Informatics confronts drug-drug interactions

10 March 2020

cites work

1 reference

Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring

21 January 2018

1 reference

Human cytochromes P450 in health and disease

21 January 2018

1 reference

Toxicological significance of mechanism-based inactivation of cytochrome p450 enzymes by drugs

21 January 2018

1 reference

Life-threatening interaction of mibefradil and beta-blockers with dihydropyridine calcium channel blockers

21 January 2018

1 reference

Interindividual variability in inhibition and induction of cytochrome P450 enzymes

21 January 2018

1 reference

Kinomics: methods for deciphering the kinome

21 January 2018

1 reference

The protein kinase complement of the human genome

21 January 2018

1 reference

Targeting cancer with small-molecular-weight kinase inhibitors

21 January 2018

1 reference

Protein kinases--the major drug targets of the twenty-first century?

21 January 2018

1 reference

Targeting cancer with small molecule kinase inhibitors

21 January 2018

1 reference

A small molecule-kinase interaction map for clinical kinase inhibitors

21 January 2018

1 reference

Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles

21 January 2018

1 reference

Clinical pharmacokinetics of tyrosine kinase inhibitors

21 January 2018

1 reference

Tyrosine kinase inhibitors as modulators of ATP binding cassette multidrug transporters: substrates, chemosensitizers or inducers of acquired multidrug resistance?

21 January 2018

1 reference

Practical management of tyrosine kinase inhibitor-associated side effects in GIST.

21 January 2018

1 reference

Computational and in vitro studies on the inhibitory effects of herbal compounds on human cytochrome P450 1A2.

21 January 2018

1 reference

Quantitative prediction of in vivo drug clearance and drug interactions from in vitro data on metabolism, together with binding and transport

21 January 2018

1 reference

Detailed analysis of grid-based molecular docking: A case study of CDOCKER-A CHARMm-based MD docking algorithm.

21 January 2018

1 reference

Influence of CYP3A4 inhibition on the steady-state pharmacokinetics of imatinib

21 January 2018

1 reference

Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome P450 3A4 substrate, in patients with chronic myeloid leukaemia

21 January 2018

1 reference

Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia

21 January 2018

1 reference

Effects of nilotinib on single-dose warfarin pharmacokinetics and pharmacodynamics: a randomized, single-blind, two-period crossover study in healthy subjects.

21 January 2018

1 reference

21 January 2018

Erlotinib hydrochloride

1 reference

Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen

21 January 2018

1 reference

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

21 January 2018

1 reference

Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer

21 January 2018

1 reference

Significant drug interaction: phenytoin toxicity due to erlotinib

21 January 2018

1 reference

Interaction of lapatinib with cytochrome P450 3A5.

21 January 2018

1 reference

Phase I and pharmacokinetic study of lapatinib and docetaxel in patients with advanced cancer

21 January 2018

1 reference

A phase I and pharmacokinetic study of lapatinib in combination with letrozole in patients with advanced cancer

21 January 2018

1 reference

Pharmacokinetic evaluation of the vinorelbine-lapatinib combination in the treatment of breast cancer patients.

21 January 2018

1 reference

Gefitinib in the treatment of advanced non-small-cell lung cancer

21 January 2018

1 reference

Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes.

21 January 2018

1 reference

Cytochrome P450-dependent metabolism of gefitinib

21 January 2018

1 reference

Vandetanib: in medullary thyroid cancer

21 January 2018

1 reference

Pharmacokinetics of vandetanib: three phase I studies in healthy subjects

21 January 2018

1 reference

A phase I study of Vandetanib in combination with vinorelbine/cisplatin or gemcitabine/cisplatin as first-line treatment for advanced non-small cell lung cancer

21 January 2018

1 reference

Crizotinib for the treatment of non-small-cell lung cancer

21 January 2018

1 reference

Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors

21 January 2018

1 reference

A phase I, dose-finding study of sunitinib combined with cisplatin and 5-fluorouracil in patients with advanced gastric cancer

21 January 2018

1 reference

Feasibility study of two schedules of sunitinib in combination with pemetrexed in patients with advanced solid tumors

21 January 2018

1 reference

An exploratory study of sunitinib plus paclitaxel as first-line treatment for patients with advanced breast cancer

21 January 2018

1 reference

Two drug interaction studies of sirolimus in combination with sorafenib or sunitinib in patients with advanced malignancies

21 January 2018

1 reference

Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia

21 January 2018

1 reference

Effects of imatinib (Glivec) on the pharmacokinetics of metoprolol, a CYP2D6 substrate, in Chinese patients with chronic myelogenous leukaemia

21 January 2018

1 reference

Comparative QSAR studies of CYP1A2 inhibitor flavonoids using 2D and 3D descriptors

21 January 2018

1 reference

Predictive three-dimensional quantitative structure-activity relationship of cytochrome P450 1A2 inhibitors

21 January 2018

1 reference

In silico prediction of drug properties

21 January 2018

1 reference

Cytochrome p450 in silico: an integrative modeling approach.

21 January 2018

1 reference

In silico methods for predicting ligand binding determinants of cytochromes P450.

21 January 2018

1 reference

In silico modelling of ADMET-a minireview of work from 2000 to 2004.

21 January 2018

1 reference

Selection and characterization of human cytochrome P450 1A2 mutants with altered catalytic properties

21 January 2018

1 reference

Adaptations for the oxidation of polycyclic aromatic hydrocarbons exhibited by the structure of human P450 1A2

21 January 2018

1 reference

A multicenter phase II study of erlotinib and sorafenib in chemotherapy-naive patients with advanced non-small cell lung cancer

21 January 2018

1 reference

Imatinib mesylate pharmacokinetics before and after sleeve gastrectomy in a morbidly obese patient with chronic myeloid leukemia.

21 January 2018

1 reference

Phase I pharmacokinetic and pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/FCP.12069

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24612223%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

1 reference